Improving care for cancer survivors with chronic conditions
Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities
This study is testing a new care approach to see if it can help cancer survivors with other health issues get better support and improve their overall health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 340 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Baylor College of Medicine Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05323409 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a new shared care model called OPTIMISE, designed to enhance the comprehensive care of cancer survivors who also have chronic comorbidities. The study involves a randomized controlled trial with 300 medically underserved patients diagnosed with breast, gastrointestinal, or hematologic cancers. Participants will be divided into two groups: one receiving standard care and the other receiving the OPTIMISE intervention, which includes tailored self-management plans and improved communication between oncologists and primary care providers. The trial aims to assess the effectiveness of this model in improving health outcomes and care transitions for these patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a recent diagnosis of early-stage breast, gastrointestinal, or hematologic cancer, who also have one or more chronic comorbidities.
Not a fit: Patients with significant cognitive impairment or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the health outcomes and quality of life for cancer survivors with chronic conditions.
How similar studies have performed: Other studies have shown promise in improving care transitions and outcomes for cancer survivors, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2) treatment with standard, definitive therapies (may include one or more modalities) 3) presence of one or more chronic comorbidities (e.g., diabetes, hypertension) and/or unhealthy lifestyle behaviors (e.g., overweight/obesity, current smoker, alcohol use) that require ongoing management during cancer treatment 4) age \>18 years 5) fluency in English or Spanish 6) ability to provide informed consent 7) assignment to a Harris Health oncologist and PCP who are willing to participate and will provide informed consent. For healthcare providers: 1) Person is an oncologist or PCP who treats patients with breast, GI, or hematologic malignancies at Harris Health BT/Smith Clinic Exclusion Criteria: * For Patients: Significant cognitive impairment or Lack of capacity to consent For Providers: None
Where this trial is running
Houston, Texas
- Baylor College of Medicine — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Hoda Badr — Baylor College of Medicine
- Study coordinator: Hoda J. Badr, PhD
- Email: hoda.badr@bcm.edu
- Phone: 7137981588
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.